HELP     Sign In
Search

Relevance to Autism

In a recent report, 13 of 21 children with mucopolysaccharidosis type IIIA (MPS IIIA), documented enzyme deficiency and SGSH gene mutations that were evaluated with the Autism Diagnostic Observation Schedule (ADOS) (module 1) met the ADOS criteria for ASD/autism (Rumsey et al., 2014).

Molecular Function

This gene encodes one of several enzymes involved in the lysosomal degradation of heparan sulfate. Mutations in this gene are associated with Sanfilippo syndrome A, one type of the lysosomal storage disease mucopolysaccaridosis III, which results from impaired degradation of heparan sulfate [MPS IIIA; MIM:252900].

External Links

        

References

Type
Title
Type of Disorder
Associated Disorders
Author, Year
Primary
Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA.
MPS IIIA
ASD
Support
Autism spectrum disorder and comorbid neurodevelopmental disorders (ASD-NDDs): Clinical and genetic profile of a pediatric cohort
ASD
DD, ID
Support
Neurological Diseases With Autism Spectrum Disorder: Role of ASD Risk Genes.
ASD
Mucopolysaccharidosis type IIIA, ID
Support
[Hyperactivity and behavioral disorders in Sanfilippo A (mucopolysaccharidosis type IIIA)--case report and review of the literature].
Recent Recommendation
Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder o...
Recent Recommendation
Sanfilippo type A: new clinical manifestations and neuro-imaging findings in patients from the same family in Israel: a case report.
MPS IIIA
ID

Rare

Variant ID
Variant Type
Allele Change
Residue Change
Inheritance Pattern
Inheritance Association
Family Type
Author, Year
 GEN601R001a 
 missense_variant 
 c.416C>T 
 p.Thr139Met 
 Familial 
 Both parents 
 Multiplex 
 GEN601R002a 
 frameshift_variant 
 c.653_654dup 
 p.Asp219TrpfsTer46 
 Familial 
  
  
 GEN601R002b 
 missense_variant 
 c.734G>A 
 p.Arg245His 
 Familial 
  
  
 GEN601R003a 
 frameshift_variant 
 c.653_654dup 
 p.Asp219TrpfsTer46 
 Familial 
 Paternal 
  
 GEN601R003b 
 missense_variant 
 c.734G>A 
 p.Arg245His 
 Familial 
 Maternal 
  
 GEN601R004 
 missense_variant 
 c.479G>A 
 p.Arg160Gln 
 De novo 
  
 Simplex 
 GEN601R005a 
 stop_gained 
 c.1272_1282del 
 p.Tyr424Ter 
 Unknown 
  
 Simplex 
 GEN601R005b 
 missense_variant 
 c.892T>C 
 p.Ser298Pro 
 Unknown 
  
 Simplex 

Common

No Common Variants Available
Chromosome
CNV Locus
CNV Type
# of studies
Animal Model
17
Duplication
 1
 
17
Duplication
 1
 
17
Duplication
 1
 
17
Duplication
 1
 
17
Deletion-Duplication
 7
 
17
Duplication
 1
 
17
Duplication
 1
 
17
Duplication
 3
 
17
Deletion-Duplication
 5
 
17
Deletion-Duplication
 29
 

Model Summary

Sgsh homozygous knockout mouse models show autistic-like behaviors due to increased proliferation of mesencephalic dopamine neurons originating during embryogenesis, which is not due to lysosomal dysfunction, but due to altered HS (heparan sulfate) function. Treatment with the dopamine D1-like receptor antagonist SCH-23390 restores hyperdopaminergia and autistic-like behaviors (De Risi M, et al, Nat. Commu. 2021).

References

Type
Title
Author, Year
Primary
Altered heparan sulfate metabolism during development triggers dopamine-dependent autistic-behaviours in models of lysosomal storage disorders

M_SGSH_1_SP_HM_G91A

Model Type: Genetic LOF
Model Genotype: Homozygous
Mutation: Spontaneous mutation resulting in a g-to-a transition point mutation at coding nucleotide 91 of the encoded mrna (c.91g>a) altered the corresponding amino acid from aspartic acid to asparagine at position 31 of the encoded protein (p.d31n).
Allele Type: Missense mutation
Strain of Origin: 129X1/SvJ * CD-1 * C57BL/6 * SJL
Genetic Background: C57BL/6
ES Cell Line: NA
Mutant ES Cell Line: NA
Model Source: 11181566

M_SGSH_1_SP_HM_G91A

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Motor strength and endurance1
Decreased
Description: Impaired neuromuscular capabilities at 8 months but not at 2 months; late onset
 Wire hang test
 8 months
General locomotor activity1
Decreased
Description: Decrease in total speed; late onset
 Open field test
 8 months
General locomotor activity: Ambulatory activity1
Increased
Description: Increase in total distance travelled; early onset
 Open field test
 2 months
General locomotor activity: Ambulatory activity1
Decreased
Description: Decrease in total distance travelled; late onset
 Open field test
 8 months
Rearing behavior1
Increased
Description: Increased rearing at 2 months but not at 8 months; early onset
 Observation of repetitive behavior
 2 months
General locomotor activity1
Increased
Description: Increase in total speed; early onset
 Open field test
 2 months
Neuronal number: dopaminergic1
Increased
Description: Increased expression of tyrosine hydroxylase and dopamine at 2-months, and p28 striatum; hyperdopaminergia; increased th+ dendritic arbors in the substantia nigra; ; no change in the number of th+ neurons in 8-month-old mutant mice; th levels in the striatum of mps-iiia mice at 8 months is reduced; early onset
 Immunohistochemistry
 2 month, E13.5, p0, p28, 8 months
Neuroreceptor levels: DA1
Abnormal
Description: Increased expression of d1r at 2 months in the nucleus accumbens and dorsomedial striatum but not in the dorsolateral striatum; d2r pre-synaptic expression is decreased in striatum; d2r postsynaptic expression is increased; early onset
 Immunohistochemistry
 2 month
Cell proliferation: neural precursors1
Increased
Description: Increase in brdu+ cells at e13.5; increased number of lmx1a+ cells, progenitor of da neurons
 Immunohistochemistry
 E13.5
Neuroreceptor levels: DA1
Abnormal
Description: Increased expression of d1r at 2 months but not d2r; early onset
 Western blot
 2 month
Neuronal number: dopaminergic1
Abnormal
Description: Increased expression of tyrosine hydroxylase and dopamine in 2-month-old striatum; hyperdopaminergia; th levels in the striatum of mps-iiia mice at 8 months is reduced; early onset
 Western blot
 2 month, 8 months
Lysosomal function: neuronal1
Abnormal
Description: Autophagosome/lysosomal dysfunction as evidenced by increased lc3-ii protein expression and an increase of one of its protein substrates, sequestosome 1 (p62/sqstm1)
 Western blot
 2 months, 8 months
Neurotransmitter release: catecholamines: dopamine1
Increased
Description: Da was increased in striatal tissue indicating that the increase in th is functional; early onset
 High-performance liquid chromatography (HPLC)
 2 month
Neuronal apoptosis1
Increased
Description: Increased number of cleaved caspase 3 and most th+ cells expressed both nuclear and perinuclear cc3+ spots at 8 months; at 2 months no cells were positive for cc3+; late onset
 Immunohistochemistry
 8 months
Macroautophagy: neuronal1
Abnormal
Description: Autophagosome/lysosomal dysfunction as evidenced by increased lc3-ii protein expression and an increase of one of its protein substrates, sequestosome 1 (p62/sqstm1)
 Western blot
 2 months, 8 months
Self grooming1
Increased
Description: Increase in self grooming at 2 months but not at 8 months; early onset
 Grooming behavior assessments
 2 months
Social dominance1
Decreased
Description: Increase in the percent retreats at 2 months but not at 8 months; early onset
 Tube test of social dominance
 2 months
Social approach1
Decreased
Description: Lack of preference for the social stimulus over the new object at 2 months but not at 8 months; early onset
 Three-chamber social approach test
 2 months
Cued or contextual fear conditioning: Memory of context1
Decreased
Description: Decrease in contextual freezing at 8 months, no change in contextual fear memory at 2 months; late onset
 Fear conditioning test
 8 months
Signaling1
Increased
Description: Da-d1r direct pathway overactivation; early onset
 Immunofluorescence staining
 2 months
Protein phosphorylation1
Increased
Description: Increased phosphorylation of d1 pathway downstream targets, the da and camp-regulated phosphoprotein p-darpp-32; early onset
 Western blot
 2 months
Exploratory activity: Habituation1
 No change
 Three-chamber social approach test
 2 months, 8 months
Protein expression: In situ protein expression1
 No change
 Immunofluorescence staining
 2 months
Neuronal number1
 No change
 Immunohistochemistry
 E13.5
Neuronal number: Inhibitory neurons1
 No change
 Western blot
 2 month
Neuronal number: Interneurons1
 No change
 Immunohistochemistry
 E13.5
Olfaction1
 No change
 Olfactory discrimination test
 2 months, 8 months
 Not Reported:

 

No Interactions Available
HELP
Copyright © 2017 MindSpec, Inc.